Table 1.
Baseline characteristics.
| Characteristics | Child–Pugh B (n = 36) (%) |
Child–Pugh A (n = 133) (%) |
p-value |
|---|---|---|---|
| Age, years, median (range) | 61.0 (42.0–85.0) | 62.0 (34.0–90.0) | 0.643 |
| Sex, male | 30 (83.3) | 109 (82.0) | 1.000 |
| ECOG performance status | 0.005 | ||
| 0/1 | 31 (86.1) | 131 (98.5) | |
| 2 | 5 (13.9) | 2 (1.5) | |
| Etiology | |||
| Hepatitis B | 21 (58.3) | 92 (69.2) | 0.236 |
| Hepatitis C | 5 (13.9) | 6 (4.5) | 0.058 |
| Alcohol | 6 (16.7) | 19 (14.3) | 0.792 |
| Unknown | 4 (11.1) | 16 (12.0) | 1.000 |
| BCLC stage | 0.358 | ||
| B | 10 (27.8) | 26 (19.5) | |
| C | 26 (72.2) | 107 (80.5) | |
| ALBI grade | <0.001 | ||
| 1 | 2 (5.6) | 91 (68.4) | |
| 2 | 30 (83.3) | 42 (31.6) | |
| 3 | 4 (2.4) | 0 (0.0) | |
| AFP ⩾400 ng/ml | 21 (58.3) | 44 (33.1) | 0.007 |
| Varices, present at baseline | 18 (50.0) | 23 (17.3) | 0.001 |
| Ascites, present at baseline | 34 (94.4) | 13 (9.8) | <0.001 |
| Macrovascular invasion | 21 (58.3) | 42 (31.6) | 0.003 |
| Main portal vein invasion | 14 (38.9) | 15 (11.3) | <0.001 |
| Extrahepatic spread | 25 (69.4) | 88 (66.2) | 0.842 |
| Lung | 15 (41.7) | 41 (30.8) | |
| Lymph node | 10 (27.8) | 32 (24.1) | |
| Bone | 4 (11.1) | 21 (15.8) | |
| Peritoneum | 2 (5.6) | 9 (6.8) | |
| Prior treatment | 20 (55.6) | 101 (76.5) | 0.020 |
| Surgery | 6 (16.7) | 44 (33.1) | |
| Radiotherapy | 8 (22.9) | 28 (21.1) | |
| TACE | 13 (36.1) | 85 (64.4) | |
| RFA | 3 (8.3) | 16 (12.0) |
AFP, alpha-fetoprotein; ALBI, albumin–bilirubin; BCLC, Barcelona clinic liver cancer; ECOG, eastern cooperative oncology group; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.